NASDAQ:COLL - Collegium Pharmaceutical Stock Price, Forecast & News

Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL."

Collegium Pharmaceutical Inc (NASDAQ:COLL) released its quarterly earnings results on Wednesday, November, 6th. The specialty pharmaceutical company reported ($0.18) EPS for the quarter, missing analysts' consensus estimates of ($0.15) by $0.03. The specialty pharmaceutical company earned $72.94 million during the quarter, compared to analysts' expectations of $74.32 million. Collegium Pharmaceutical had a negative net margin of 3.86% and a negative return on equity of 13.14%. The company's quarterly revenue was up 3.9% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.50) earnings per share. View Collegium Pharmaceutical's Earnings History.

Collegium Pharmaceutical is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Collegium Pharmaceutical.

6 Wall Street analysts have issued 12 month price objectives for Collegium Pharmaceutical's stock. Their forecasts range from $22.00 to $36.00. On average, they anticipate Collegium Pharmaceutical's stock price to reach $29.33 in the next twelve months. This suggests a possible upside of 40.0% from the stock's current price. View Analyst Price Targets for Collegium Pharmaceutical.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Collegium Pharmaceutical.

News headlines about COLL stock have been trending extremely negative recently, according to InfoTrie Sentiment. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Collegium Pharmaceutical earned a coverage optimism score of -4.5 on InfoTrie's scale. They also gave news articles about the specialty pharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for Collegium Pharmaceutical.

Collegium Pharmaceutical saw a increase in short interest in December. As of December 31st, there was short interest totalling 2,040,000 shares, an increase of 22.9% from the December 15th total of 1,660,000 shares. Based on an average daily volume of 444,800 shares, the days-to-cover ratio is currently 4.6 days. Currently, 7.0% of the company's stock are short sold. View Collegium Pharmaceutical's Current Options Chain.

Some companies that are related to Collegium Pharmaceutical include Uniqure (QURE), Epizyme (EPZM), ArQule (ARQL), Zogenix (ZGNX), ChemoCentryx (CCXI), Amicus Therapeutics (FOLD), Karuna Therapeutics (KRTX), Arena Pharmaceuticals (ARNA), Ra Pharmaceuticals (RARX), Synthorx (THOR), Turning Point Therapeutics (TPTX), Aurinia Pharmaceuticals (AUPH), Heron Therapeutics (HRTX), Prestige Consumer Healthcare (PBH) and Eidos Therapeutics (EIDX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Collegium Pharmaceutical investors own include GALAPAGOS NV/S (GLPG), AbbVie (ABBV), NVIDIA (NVDA), Advanced Micro Devices (AMD), Celgene (CELG), Bausch Health Companies (BHC), Canopy Growth (CGC), GW Pharmaceuticals PLC- (GWPH), Intercept Pharmaceuticals (ICPT) and Ocular Therapeutix (OCUL).

(COLL) raised $75 million in an initial public offering on Thursday, May 7th 2015. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.

Collegium Pharmaceutical's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Strs Ohio (0.11%) and Campbell & CO Investment Adviser LLC (0.04%). Company insiders that own Collegium Pharmaceutical stock include Alison B Fleming, David Hirsch, Joseph Ciaffoni, Michael Thomas Heffernan, Paul Brannelly and Scott Dreyer. View Institutional Ownership Trends for Collegium Pharmaceutical.

COLL stock was sold by a variety of institutional investors in the last quarter, including Strs Ohio. Company insiders that have sold Collegium Pharmaceutical company stock in the last year include David Hirsch, Joseph Ciaffoni, Michael Thomas Heffernan and Scott Dreyer. View Insider Buying and Selling for Collegium Pharmaceutical.

COLL stock was acquired by a variety of institutional investors in the last quarter, including Campbell & CO Investment Adviser LLC. View Insider Buying and Selling for Collegium Pharmaceutical.

Shares of COLL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of COLL stock can currently be purchased for approximately $20.95.

Collegium Pharmaceutical has a market capitalization of $702.45 million and generates $280.41 million in revenue each year. The specialty pharmaceutical company earns $-39,130,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis. Collegium Pharmaceutical employs 266 workers across the globe.View Additional Information About Collegium Pharmaceutical.

The official website for Collegium Pharmaceutical is http://www.collegiumpharma.com/.

Collegium Pharmaceutical's mailing address is 100 Technology Center Drive, Stoughton MA, 02072. The specialty pharmaceutical company can be reached via phone at 781-713-3699.